The Immune Response Corporation Names Dr. Elias Nyberg as Vice President, Regulatory Affairs

Apr 27, 2001, 01:00 ET from The Immune Response Corporation

    SAN DIEGO, April 27 /PRNewswire/ -- The Immune Response Corporation
 (Nasdaq:   IMNR) today announced that Elias Nyberg, DVM, BVSc(hons), MACVS,
 MRCVS, MBA, has been named Vice President, Regulatory Affairs.  Dr. Nyberg
 brings expertise in global regulatory affairs to the Company and has been
 responsible for the successful launch of several pharmaceutical products
 during his career.  Dr. Nyberg has extensive experience in regulatory affairs
 and quality assurance.  His expertise includes regulatory strategy,
 coordinating clinical trials and knowledge of FDA and European regulations and
 guidelines.  While at INC Research/PRA International Inc., Dr. Nyberg
 developed and assessed regulatory strategy for clients and managed the entire
 quality assurance process for the company.  Prior to joining INC Research/PRA
 International Inc., Dr. Nyberg was Worldwide Director of Regulatory Affairs
 for Astra Arcus AB.  Previously Dr. Nyberg served as Head of Technical
 Services and Regulatory Affairs for Pfizer Pharmaceuticals, Northern European
 Division, where he consecutively launched three new products.  Prior to
 Pfizer, Dr. Nyberg was Head of Technical Services and Regulatory Affairs and
 Director of Worldwide Global Anthelmintic Business Development at Ciba-Geigy
 Animal Health, World Headquarters.
     "The Immune Response Corporation has numerous innovative products focused
 on immune-based therapies," said Dr. Nyberg.  "I look forward to moving these
 products toward the goal of achievement of commercial approval and into the
 marketplace."
     "We are very pleased to have Dr. Nyberg join our executive management
 team.  His expertise in worldwide regulatory affairs, including pre-clinical,
 clinical, FDA, and the European Agency for the Evaluation of Medicinal
 Products (EMEA) experience will be a key asset to the Company as we continue
 to develop our products," said Dennis J. Carlo, Ph.D., President and Chief
 Executive Officer of The Immune Response Corporation.
 
     The Immune Response Corporation is a biopharmaceutical company based in
 Carlsbad, California, developing immune-based therapies to induce specific
 T-cell responses for the treatment of HIV, autoimmune diseases and cancer.  In
 addition, the Company is developing a targeted non-viral delivery technology
 for gene therapy, which is designed to enable the delivery of genes directly
 to the liver via intravenous injection.
 
     NOTE:  News releases are available through PR Newswire Company News
 On-Call fax service.  For a menu of available news releases or to retrieve a
 specific release made by The Immune Response Corporation, please call
 800-758-5804, extension 434675.  Please retain these numbers for future
 reference.  Company information can also be located on the Internet Web Site:
 http://www.imnr.com.
 
     This news release contains forward-looking statements.  Actual results
 could vary materially from those expected due to a variety of risk factors,
 including, but not limited to, whether preclinical data can be replicated in
 clinical trials, whether if initiated clinical trials will be successfully
 concluded and whether a product will be approved for marketing or be
 successfully commercialized.  Those factors are discussed more thoroughly in
 The Immune Response Corporation's SEC filings, including but not limited to
 its report on Form 10-K for the year ended December 31, 2000.  The Company
 undertakes no obligation to publicly release the result of any revisions to
 these forward-looking statements which may be made to reflect events or
 circumstances after the date hereof or to reflect the occurrence of
 unanticipated events.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X20717461
 
 

SOURCE The Immune Response Corporation
    SAN DIEGO, April 27 /PRNewswire/ -- The Immune Response Corporation
 (Nasdaq:   IMNR) today announced that Elias Nyberg, DVM, BVSc(hons), MACVS,
 MRCVS, MBA, has been named Vice President, Regulatory Affairs.  Dr. Nyberg
 brings expertise in global regulatory affairs to the Company and has been
 responsible for the successful launch of several pharmaceutical products
 during his career.  Dr. Nyberg has extensive experience in regulatory affairs
 and quality assurance.  His expertise includes regulatory strategy,
 coordinating clinical trials and knowledge of FDA and European regulations and
 guidelines.  While at INC Research/PRA International Inc., Dr. Nyberg
 developed and assessed regulatory strategy for clients and managed the entire
 quality assurance process for the company.  Prior to joining INC Research/PRA
 International Inc., Dr. Nyberg was Worldwide Director of Regulatory Affairs
 for Astra Arcus AB.  Previously Dr. Nyberg served as Head of Technical
 Services and Regulatory Affairs for Pfizer Pharmaceuticals, Northern European
 Division, where he consecutively launched three new products.  Prior to
 Pfizer, Dr. Nyberg was Head of Technical Services and Regulatory Affairs and
 Director of Worldwide Global Anthelmintic Business Development at Ciba-Geigy
 Animal Health, World Headquarters.
     "The Immune Response Corporation has numerous innovative products focused
 on immune-based therapies," said Dr. Nyberg.  "I look forward to moving these
 products toward the goal of achievement of commercial approval and into the
 marketplace."
     "We are very pleased to have Dr. Nyberg join our executive management
 team.  His expertise in worldwide regulatory affairs, including pre-clinical,
 clinical, FDA, and the European Agency for the Evaluation of Medicinal
 Products (EMEA) experience will be a key asset to the Company as we continue
 to develop our products," said Dennis J. Carlo, Ph.D., President and Chief
 Executive Officer of The Immune Response Corporation.
 
     The Immune Response Corporation is a biopharmaceutical company based in
 Carlsbad, California, developing immune-based therapies to induce specific
 T-cell responses for the treatment of HIV, autoimmune diseases and cancer.  In
 addition, the Company is developing a targeted non-viral delivery technology
 for gene therapy, which is designed to enable the delivery of genes directly
 to the liver via intravenous injection.
 
     NOTE:  News releases are available through PR Newswire Company News
 On-Call fax service.  For a menu of available news releases or to retrieve a
 specific release made by The Immune Response Corporation, please call
 800-758-5804, extension 434675.  Please retain these numbers for future
 reference.  Company information can also be located on the Internet Web Site:
 http://www.imnr.com.
 
     This news release contains forward-looking statements.  Actual results
 could vary materially from those expected due to a variety of risk factors,
 including, but not limited to, whether preclinical data can be replicated in
 clinical trials, whether if initiated clinical trials will be successfully
 concluded and whether a product will be approved for marketing or be
 successfully commercialized.  Those factors are discussed more thoroughly in
 The Immune Response Corporation's SEC filings, including but not limited to
 its report on Form 10-K for the year ended December 31, 2000.  The Company
 undertakes no obligation to publicly release the result of any revisions to
 these forward-looking statements which may be made to reflect events or
 circumstances after the date hereof or to reflect the occurrence of
 unanticipated events.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X20717461
 
 SOURCE  The Immune Response Corporation

RELATED LINKS

http://www.imnr.com